SCHEMBL2491471

SCHEMBL2491471

CC(C)(NC(=O)c1cccc(C(F)(F)F)c1F)C(=O)Nc1nc(-c2ccccc2)c(Cc2ccccc2)s1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.45
PLTP P55058 5/20 0.44
DGAT1 O75907 2/20 0.42
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
ALDH1A1 P00352 4/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 1/20 0.38
XIAP P98170 1/20 0.37
KAT6A Q92794 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2363571 0.90 PLTP (0.43) RORCPLTPDGAT1ADORA2AADORA1
SCHEMBL2490168 0.84 PLTP (0.51) RORCPLTPDGAT1ADORA2AADORA1
SCHEMBL2484995 0.83 PLTP (0.51) RORCPLTPDGAT1ADORA2AADORA1
SCHEMBL2491127 0.82 NPC1 (0.48) RORCPLTPDGAT1ADORA2AADORA1
SCHEMBL2490496 0.81 PLTP (0.52) RORCPLTPDGAT1ADORA2AADORA1
SCHEMBL2487621 0.80 PLTP (0.49) RORCPLTPDGAT1ADORA2AADORA1
SCHEMBL2317569 0.80 AR (0.52) RORCPLTPDGAT1ALDH1A1TP53
SCHEMBL2487852 0.79 RORC (0.49) RORCPLTPDGAT1ADORA2AADORA1
SCHEMBL2485677 0.79 PLTP (0.51) RORCPLTPDGAT1ADORA2AADORA1
SCHEMBL2316532 0.79 RORC (0.49) RORCPLTPDGAT1ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
CN-102119047-A Heteroaryl derivatives as DGAT1 inhibitors NOVARTIS AG 2011-07-06 CN disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 RORC 1166/4885PLTP 575/4885DGAT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.